Eupraxia to Present Positive EP-104GI EoE Data at Digestive Disease Week, Host KOL Investor Event
Summary
Eupraxia Pharmaceuticals will present detailed positive 36-week data from its Phase 1b/2 RESOLVE trial for EP-104GI in eosinophilic esophagitis at the upcoming Digestive Disease Week meeting and host a virtual investor event with key opinion leaders.
Key Events
-
DDW Presentations Scheduled
Eupraxia will present four abstracts at the Digestive Disease Week (DDW) Annual Meeting from May 2-5, 2026, in Chicago, Illinois.
-
Positive Clinical Data for EP-104GI
Presentations will include 36-week data from the Phase 1b/2 RESOLVE trial of EP-104GI for eosinophilic esophagitis (EoE), highlighting persistent histological improvements, improved endoscopic features, and durability of dysphagia improvements.
-
KOL Investor Event
The company will host a virtual investor event on May 4, 2026, featuring key opinion leaders to discuss recurrent esophageal strictures and the potential of EP-104GI for prevention.
Analysis
This filing provides further details and a platform for Eupraxia to highlight the positive 36-week data from its RESOLVE trial for EP-104GI in eosinophilic esophagitis, which was initially announced yesterday. The presentation of four abstracts at a major medical conference like Digestive Disease Week, coupled with a dedicated investor event featuring key opinion leaders, significantly increases the visibility and validation of the company's lead product candidate. Investors should monitor these presentations for deeper insights into the clinical profile and potential of EP-104GI, particularly regarding its long-term efficacy and potential to prevent esophageal strictures.
At the time of this filing, EPRX was trading at $7.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $431.8M. The 52-week trading range was $3.38 to $9.32. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.